GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (FRA:9VC) » Definitions » Retained Earnings

ATAI Life Sciences NV (FRA:9VC) Retained Earnings : €-668.70 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. ATAI Life Sciences NV's retained earnings for the quarter that ended in Dec. 2024 was €-668.70 Mil.

ATAI Life Sciences NV's quarterly retained earnings declined from Jun. 2024 (€-589.88 Mil) to Sep. 2024 (€-595.79 Mil) and declined from Sep. 2024 (€-595.79 Mil) to Dec. 2024 (€-668.70 Mil).

ATAI Life Sciences NV's annual retained earnings declined from Dec. 2022 (€-481.62 Mil) to Dec. 2023 (€-505.21 Mil) and declined from Dec. 2023 (€-505.21 Mil) to Dec. 2024 (€-668.70 Mil).


ATAI Life Sciences NV Retained Earnings Historical Data

The historical data trend for ATAI Life Sciences NV's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Retained Earnings Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial -156.18 -316.66 -481.62 -505.21 -668.70

ATAI Life Sciences NV Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -505.21 -531.44 -589.88 -595.79 -668.70

ATAI Life Sciences NV Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


ATAI Life Sciences NV  (FRA:9VC) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


ATAI Life Sciences NV Business Description

Traded in Other Exchanges
Address
Wallstrasse 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

ATAI Life Sciences NV Headlines

No Headlines